News
Stay up-to-date on our latest news.
Stay up-to-date on our latest news.
Feb 01, 2021
Clover and Dynavax Announce Planned Global Phase 2/3 Efficacy Trial of Adjuvanted COVID-19 Vaccine CandidateDec 04, 2020
Clover Biopharmaceuticals Announces Positive Phase 1 Data for its Adjuvanted S-Trimer COVID-19 Vaccine CandidatesNov 03, 2020
CEPI extends partnership with Clover Biopharmaceuticals to fund COVID-19 vaccine candidate through global Phase 2/3 study to licensureSep 25, 2020
Clover Announces Formation of a Global Scientific Advisory Board for its COVID-19 Vaccine ProgramSep 25, 2020
Clover Announces Positive Preclinical Data and Updates on Phase 1 Study for its Adjuvanted S-Trimer COVID-19 Vaccine CandidateJul 08, 2020
CEPI expands partnership with Clover to rapidly advance development and manufacture of COVID-19 vaccine candidateJun 19, 2020
Clover Initiates Phase 1 Clinical Trial for COVID-19 Vaccine CandidateJun 08, 2020
GL Ventures Completes $24 Million Series B-2 Investment in Clover BiopharmaceuticalsApr 27, 2020
CEPI announces COVID-19 vaccine development partnership with Clover Biopharmaceuticals' Australian SubsidiaryMar 24, 2020
Dynavax and Clover Biopharmaceuticals Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with CpG 1018 Adjuvant
